Product name

Vasoconstrictor Peptide Urotensin II-Converting Enzyme Inhibitors

Summary

A method for the identification of inhibitors of an urotensin-II-converting enzyme is available for the first time.

Organization name

ipal GmbH

Profile

Human urotensin-II is one of the most potent vasoconstrictor peptides identified to date. High plasma levels have been detected in patients with essential hypertension, heart failure and atherosclerosis. Urotensin-II gets released and activated by cleavage of its prohormone prourotensin- II which is mediated by an UCE.

The new technology allows the measurement of UCE-activity in a protein sample with the help of a massspectrometry-assisted enzyme screening (MES-assay) developed by the inventor. The validation of the enzyme activity is based on the mass spectrometric detection of its product, the Urotensin-II and the decrease of its educt, the UCEsubstrate / pro-urotensin-II.

Furthermore, the method enables a purification procedure of a urotensin-II-converting enzyme-containing sample by chromatographic purification with the help of protein-purification parameter screening (PPS) as well as the identification of the purified enzyme by peptide mass finger printing / mass spectroscopy. By measurement of the enzyme activity, potential inhibitors can be tested on their impact to inhibit UCE-activity. Since urotensin-II is a strong vasoconstrictor peptide, identified inhibitors of its generating enzyme UCE represent a new drug class of antihypertensives with high potential on the drug market.

Competitiveness  

• No UCE has been identified before
• First published method for the measurement of UCE-activity and for the identification of UCE-inhibitors
• Identified UCE-inhibitors represent a new drug class of antihypertensives
• New antihypertensive drugs are needed since many antihypertensives present on the drug market show unintentional adverse effects or are ineffective in certain patient groups
• Ongoing increasing R&D activities in the field of hypertension therapeutics  

A German Patent Application has been filed. Additional information is provided in the attached pdf.

The technology is offerd by IPAL.

Contact

ipal GmbH
Rafaela Kunz
rafaela.kunz(at)ipal.de

About IPAL

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.

 

Description File

 06074_UrotensinII_inhibitors.pdf

URL

http://www.ipal.de/en/technology_offers/life_sciences/

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney